title: Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.
authors.affiliation: Pittsburgh Transplant Institute, Pennsylvania.
authors.forename: S
authors.initials: S
authors.lastname: Takaya
authors.forename: O
authors.initials: O
authors.lastname: Bronsther
authors.forename: K
authors.initials: K
authors.lastname: Abu-Elmagd
authors.forename: H
authors.initials: H
authors.lastname: Ramos
authors.forename: J J
authors.initials: JJ
authors.lastname: Fung
authors.forename: S
authors.initials: S
authors.lastname: Todo
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D016559:Tacrolimus / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003404:Creatinine; D000527:Alprostadil; D016559:Tacrolimus